Cerus (CERS) Tops Q4 EPS by 2c, provides product guidance

Cerus (NASDAQ: CERS) reported Q4 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $53.34 million versus the consensus estimate of $53.62 million.

Reiterating 2024 Product Revenue Guidance

The Company expects full-year 2024 product revenue will be in the range of $172 million to $175 million. Included in this range is full-year 2024 INTERCEPT Fibrinogen Complex revenue guidance between $8 million to $10 million.

For earnings history and earnings-related data on Cerus (CERS) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Bernstein SocGen on Oracle (ORCL): 'Next catalyst is FAM'
• Macy's (M) Stock: Street Underestimates Earnings Pressure From Share Loss, Says Analyst